Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
635.98
+6.30 (+1.00%)
Streaming Delayed Price
Updated: 12:00 PM EDT, May 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
472,093
Open
630.49
Bid (Size)
635.66 (240)
Ask (Size)
636.29 (760)
Prev. Close
629.68
Today's Range
616.02 - 636.62
52wk Range
476.49 - 821.11
Shares Outstanding
91,779,465
Dividend Yield
0.59%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Regeneron (REGN) Shares Are Trading Lower Today
May 18, 2026
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet t...
Via
StockStory
What's going on in today's session: S&P500 movers
↗
May 18, 2026
Via
Chartmill
Performance
YTD
-18.1%
-18.1%
1 Month
-15.1%
-15.1%
3 Month
-19.9%
-19.9%
6 Month
-9.7%
-9.7%
1 Year
+6.6%
+6.6%
More News
Read More
Unusual volume S&P500 stocks in Monday's session
↗
May 18, 2026
Via
Chartmill
Discover which S&P500 stocks are making waves on Monday.
↗
May 18, 2026
Via
Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
↗
May 18, 2026
Via
Chartmill
Which S&P500 stocks are moving before the opening bell on Monday?
↗
May 18, 2026
Via
Chartmill
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
May 18, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
May 15, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026
From
Society For Science
Via
GlobeNewswire
3 Reasons to Sell REGN and 1 Stock to Buy Instead
May 14, 2026
Via
StockStory
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
↗
May 08, 2026
Via
The Motley Fool
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
May 08, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Is This Biotech Stock a Buy After a Groundbreaking Approval?
↗
May 08, 2026
Via
The Motley Fool
5 Must-Read Analyst Questions From Regeneron’s Q1 Earnings Call
May 06, 2026
Via
StockStory
Topics
Earnings
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
May 05, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
↗
May 02, 2026
Via
The Motley Fool
1 Cash-Producing Stock Worth Investigating and 2 Facing Headwinds
May 01, 2026
Via
StockStory
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings
↗
April 30, 2026
Via
Benzinga
REGN Q1 Deep Dive: Product Expansion Drives Growth, Margin Pressures Draw Scrutiny
April 30, 2026
Via
StockStory
3 Healthcare Stocks We Keep Off Our Radar
April 30, 2026
Via
StockStory
Why Regeneron (REGN) Shares Are Getting Obliterated Today
April 29, 2026
Via
StockStory
Topics
Artificial Intelligence
World Trade
Exploring the top movers within the S&P500 index during today's session.
↗
April 29, 2026
Via
Chartmill
These S&P500 stocks have an unusual volume in today's session
↗
April 29, 2026
Via
Chartmill
Regeneron (REGN) Q1 2026 Earnings Transcript
↗
April 29, 2026
Via
The Motley Fool
Which S&P500 stocks are moving on Wednesday?
↗
April 29, 2026
Via
Chartmill
Frequently Asked Questions
Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 635.98
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 05/19/26 12:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 58.37B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 58B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today